Intensive weight-loss and metabolic-syndrome management.
How does it work?
Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon and strongly suppresses appetite.
Best for
Patients with obesity or type 2 diabetes–spectrum issues where dual incretin therapy is appropriate.
Therapeutic services are required by law to include VAT, as they are classified differently from other healthcare services. This ensures compliance with current legislation.